TALL-104

N/A

Report date: 2022/09/01 20:01:19

Base Information

Drug NameTALL-104

Drug Alias NameTALL-104 cell therapyTALL-104ABIO-0501ABIO-05/01

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapy

Mechanisms of ActionCell death stimulantsT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsLeukemia, Myelogenous, Chronic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesWistar Institute Abiogen Pharma Spa

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbiogen Pharma Spa The University Of Texas MD Anderson Cancer Center

Active IndicationsN/A

Inactive IndicationsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A